IN-CUMMINS
21.8.2019 15:03:15 CEST | Business Wire | Press release
Cummins Inc. (NYSE: CMI) announced today that President and COO, Rich Freeland will retire after forty years of service with Cummins.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190821005396/en/
As part of Cummins’ successions plans, the following leadership appointments are also taking place, all of which are effective October 15.
- Distribution President Tony Satterthwaite will succeed Freeland as President and COO.
- Components President Tracy Embree will succeed Satterthwaite as Distribution Business President.
- Chief Technical Officer Jennifer Rumsey will succeed Embree as Components Business President.
- Jim Fier will succeed Rumsey as Chief Technical Officer.
“I want to personally thank Rich for his many contributions to Cummins and his friendship and support over the 25 years I have known and worked with him,” said Tom Linebarger, Chairman and CEO, Cummins Inc. “He is one of the most effective leaders in Cummins history because of his ability to connect with customers, develop our employees, and his deep understanding of nearly every element of our business. Equally impressive to me is that Rich has accomplished these things in an unassuming, humble manner. He has an unrelenting commitment to our core values and always makes the right decisions for our business, for our people and our communities. His positive impact is vast, and Rich will be missed by many, many people inside and outside of Cummins.”
“I also want to congratulate Tony, Tracy, Jennifer and Jim on their new roles,” added Linebarger. “They are all incredibly talented leaders who have demonstrated their ability to lead people, drive results and make Cummins a stronger company, and a better place to work. I am excited for each of them and looking forward to working with them as we drive our company forward focusing on our growth plans and continuing to deliver value to our customers and all our stakeholders.”
Rich Freeland:
Freeland joined Cummins in 1979 as a second shift foreman in the Parts Distribution Center in Columbus, Indiana, the day after his graduation from Purdue University. Freeland spent his entire 40-year career with Cummins. Over his career, Freeland successfully led three of Cummins’ five business segments and he was responsible for all of Cummins’ global operations as Chief Operating Officer, a position he has held since 2014. Freeland will also resign from the Board of Directors of the company, effective October 15, 2019.
Tony Satterthwaite
Tony Satterthwaite, currently the Distribution Business President that employs approximately 16,000 people worldwide, will succeed Freeland as President and Chief Operating Officer of Cummins. Satterthwaite joined Cummins in 1988 and has held leadership positions throughout the company’s businesses and operations.
Prior to his current position, Satterthwaite led Cummins Power Generation from 2008 to 2015. Under his leadership, the Power Generation business unit engineered the power industry’s only full range of large stationary generator sets to meet the U.S. Environmental Protection Agency’s current Tier 4 standards. The business won major new military contracts, expanded the product footprint and invested in new technologies.
In addition to successfully leading two global business units, Satterthwaite has worked relentlessly over his career to solve problems that drive business results and improve customer satisfaction. Satterthwaite has a strong reputation for understanding the details of Cummins’ business at all levels. He has lived for extensive periods in Asia, Europe, and the US and has visited nearly every one of Cummins’ locations throughout his long career.
Tracy Embree
Tracy Embree will succeed Sattherthwaite as Distribution Business President. Embree has led the Components Business for five years, bringing the business to record sales and profitability. Under her leadership, the component product lines expanded to include transmissions. In addition, Cummins has grown market share around the world. Embree has held many leadership roles in different areas of the business, including several critical customer-facing roles.
Jennifer Rumsey
Jennifer Rumsey will succeed Embree as Components Business President. Rumsey has served in technical leadership roles since she joined Cummins in 2000 and currently serves as Chief Technical Officer. Rumsey has held roles in engineering leadership, new product program leadership, controls, aftertreatment technology, advanced engineering, and quality. Rumsey has been involved in some of the most important products and technologies that the company has developed over the last 19 years.
Jim Fier
Jim Fier will succeed Rumsey as Chief Technical Officer. Fier has been with Cummins for more than 30 years and is a highly accomplished engineering leader. In engine development, Fier is recognized as one of the most technically skilled and experienced engineers in the industry.
Fier has demonstrated the ability to build strong teams and cultivate confidence and credibility among our customers and many different partners across the industry.
About Cummins
Cummins Inc., a global technology leader, is a corporation of complementary business segments that designs, manufactures, distributes and services a broad portfolio of power solutions. The company’s products range from diesel and natural gas engines to hybrid and electric platforms, as well as related technologies, including transmissions, battery systems, fuel systems, controls, air handling, filtration, emission solutions, and power generation systems. Headquartered in Columbus, Indiana (U.S.), since its founding in 1919, Cummins employs approximately 62,600 people committed to powering a more prosperous world through three global corporate responsibility priorities critical to healthy communities: education, environment and equality of opportunity. Cummins serves customers in approximately 190 countries and territories through a network of approximately 600 company-owned and independent distributor locations, and over 7,600 dealer locations. In 2018, the company earned about $2.1 billion on sales of $23.8 billion.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190821005396/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
